1. Home
  2. GHRS vs UTL Comparison

GHRS vs UTL Comparison

Compare GHRS & UTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GHRS
  • UTL
  • Stock Information
  • Founded
  • GHRS 2018
  • UTL 1984
  • Country
  • GHRS Ireland
  • UTL United States
  • Employees
  • GHRS N/A
  • UTL N/A
  • Industry
  • GHRS Biotechnology: Pharmaceutical Preparations
  • UTL Power Generation
  • Sector
  • GHRS Health Care
  • UTL Utilities
  • Exchange
  • GHRS Nasdaq
  • UTL Nasdaq
  • Market Cap
  • GHRS 774.1M
  • UTL 889.7M
  • IPO Year
  • GHRS 2021
  • UTL N/A
  • Fundamental
  • Price
  • GHRS $13.53
  • UTL $48.72
  • Analyst Decision
  • GHRS Strong Buy
  • UTL Hold
  • Analyst Count
  • GHRS 9
  • UTL 1
  • Target Price
  • GHRS $29.33
  • UTL $55.00
  • AVG Volume (30 Days)
  • GHRS 274.3K
  • UTL 76.9K
  • Earning Date
  • GHRS 11-07-2025
  • UTL 11-03-2025
  • Dividend Yield
  • GHRS N/A
  • UTL 3.67%
  • EPS Growth
  • GHRS N/A
  • UTL N/A
  • EPS
  • GHRS N/A
  • UTL 2.91
  • Revenue
  • GHRS N/A
  • UTL $493,800,000.00
  • Revenue This Year
  • GHRS N/A
  • UTL $6.14
  • Revenue Next Year
  • GHRS N/A
  • UTL $9.04
  • P/E Ratio
  • GHRS N/A
  • UTL $16.89
  • Revenue Growth
  • GHRS N/A
  • UTL N/A
  • 52 Week Low
  • GHRS $6.72
  • UTL $44.61
  • 52 Week High
  • GHRS $20.50
  • UTL $61.51
  • Technical
  • Relative Strength Index (RSI)
  • GHRS 50.01
  • UTL 56.60
  • Support Level
  • GHRS $12.50
  • UTL $47.68
  • Resistance Level
  • GHRS $14.44
  • UTL $50.30
  • Average True Range (ATR)
  • GHRS 1.04
  • UTL 1.09
  • MACD
  • GHRS 0.01
  • UTL -0.06
  • Stochastic Oscillator
  • GHRS 45.24
  • UTL 63.74

About GHRS GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

About UTL UNITIL Corporation

Unitil Corp is a holding company, through its subsidiaries it is engaged in the local distribution of electricity and natural gas throughout its service territories in the states of New Hampshire, Massachusetts, and Maine. The Company has two operating and reportable segments: Utility Electric Operations and Utility Gas Operations. Majority of revenue is gained from Electric Segment.

Share on Social Networks: